Generic Medicine Info
Atovaquone: Should be taken with food.
Atovaquone + proguanil hydrochloride: Should be taken with food.
Hypersensitivity to atovaquone.
Special Precautions
Patient w/ GI disorders (e.g. diarrhoea, vomiting), pulmonary disease (due to causes other than pneumocystis pneumonia). Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor hepatic function at baseline and during treatment. Assess patient's food tolerance, post-dose vomiting and diarrhoea.
Adverse Reactions
Nausea, vomiting, diarrhoea, headache, cough; rash, pruritus, fever, anorexia, depression, dizziness, insomnia, hyponatraemia, elevated liver enzyme values, haematological disturbance (e.g. anaemia, neutropenia). Rarely, hypersensitivity reactions (e.g. angioedema, anaphylaxis, urticaria, vasculitis), cholestasis, hepatitis.
Potentially Fatal: Rarely, liver failure.
Drug Interactions
Decreased plasma concentration w/ metoclopramide, tetracycline, rifamycin derivatives (e.g. rifampicin, rifabutin), efavirenz or boosted protease-inhibitors (e.g. ritonavir). Slightly decreased plasma concentration w/ aciclovir, antidiarrhoeals, benzodiazepines, cephalosporins, laxatives, opioids, paracetamol. May decrease the rate of metabolism and increase the plasma concentration of zidovudine. May decrease the trough and area under the curve concentration of indinavir. May increase the plasma concentration of etoposide. May displace other highly protein-bound drugs from plasma-protein binding sites.
CIMS Class
ATC Classification
P01AX06 - atovaquone ; Belongs to the class of other agents used in the treatment amoebiasis and other protozoal diseases.
Disclaimer: This information is independently developed by CIMS based on atovaquone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in